UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) | Israel | Not applicable | | --- | --- | | (State or other jurisdic ...

Lifeward (LFWD) Q2 2025 Earnings Call August 14, 2025 08:30 AM ET Speaker0Good day, and welcome to the second quarter twenty twenty five LifeWorks conference call. All participants will be in listen only mode. If you do need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. Please note this event has been recorded.I would now like to turn the conference over to Mr. Almohadar. Please go ahead ...

Exhibit 99.1 Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, August 14, 2025 – Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three and six months ended Jun ...

Core Viewpoint - Lifeward Ltd. is set to release its second quarter 2025 financial results on August 14, 2025, before market opening, highlighting its ongoing commitment to innovation in medical technology for individuals with physical limitations or disabilities [1]. Company Overview - Lifeward designs, develops, and commercializes solutions aimed at physical rehabilitation and recovery, with a mission to drive innovation that transforms the lives of individuals with disabilities [3]. - The company's product portfolio includes notable innovations such as the ReWalk Exoskeleton, AlterG Anti-Gravity system, MyoCycle FES System, and ReStore Exo-Suit, which provide functional and health benefits in both clinical and home settings [3]. Financial Communication - The financial results will be discussed in a conference call and live webcast hosted by the President and CEO, Mark Grant, along with the Vice President of Finance, Almog Adar, scheduled for 8:30 a.m. EDT on the same day [2]. - Access to the conference call will be available through various toll-free numbers for different regions, and a live webcast will be accessible via the company's website [2].

Core Viewpoint - Lifeward Ltd. has expanded its distribution partnership with SportsMed Products Ltd. to include the United Arab Emirates and the Gulf Cooperation Council region, enhancing the reach of its AlterG product lines [1][2]. Company Overview - Lifeward Ltd. is a global leader in innovative medical technology focused on transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [3]. - The company offers a range of products including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, and has operations in the United States, Israel, and Germany [3]. Partnership Details - The partnership with SportsMed Products Ltd. aims to leverage their established presence in the UK and Ireland, where they have sold over 300 AlterG devices since becoming the exclusive dealer in 2015 [2]. - SportsMed Performance Trading LLC, operating in the GCC, has launched a demo zone in Dubai for customers to experience the latest AlterG NEO+ system [2]. Market Expansion - The expansion into the UAE and GCC is seen as a critical step for Lifeward to enhance the global reach and success of its AlterG product lines [2].

Company Overview - MedRhythms, Inc. is pioneering next-generation neurotherapeutics aimed at improving walking, mobility, and related functional outcomes through a proprietary technology platform that integrates sensors, software, and music with advanced neuroscience [5] - The company has developed a pipeline of products targeting various neurological conditions, including stroke, multiple sclerosis, and Parkinson's disease [5] Leadership Transition - Larry Jasinski has been appointed as the new Chief Executive Officer, effective immediately, succeeding co-founder Brian Harris, who will transition to Chief Scientific Officer [1][3] - Jasinski brings over 30 years of executive leadership experience in the medical device and neurotechnology industries, including a successful IPO at Lifeward and national reimbursement for the first exoskeleton system for spinal cord injury [2] Strategic Growth Plans - The appointment of Jasinski is seen as a critical inflection point for MedRhythms, as the company prepares for national expansion of its home-use products, InTandem® for chronic stroke and Movive™ for Parkinson's disease, both of which are FDA-listed Class II devices [4] - The company aims to accelerate market adoption and build on its clinical foundation to reach more patients with chronic health and mobility conditions [4] Market Position and Vision - MedRhythms has established clinical data supporting the effectiveness of its products and operates in sizable market segments, having gained coverage from CMS and other entities [4] - The company is focused on transforming patients' lives and is positioned to become a valuable business entity in the neurorehabilitation space [4]

Core Viewpoint - Lifeward Ltd. has successfully closed a public offering of 4,000,000 ordinary shares and accompanying warrants, raising approximately $2.6 million in gross proceeds, which will be used for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering price was set at $0.65 per ordinary share and associated ordinary warrant, with the warrants having an exercise price of $0.65 and expiring five years from the issuance date [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for the offering [2]. - The potential additional gross proceeds from the exercise of the ordinary warrants, if fully exercised, could amount to another $2.6 million [3]. Group 2: Company Overview - Lifeward Ltd. is a leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [1]. - The company offers a range of products including the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, focusing on rehabilitation and recovery [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany, with a mission to drive innovation in the field of physical rehabilitation [6].

Core Viewpoint - Lifeward Ltd. has announced a public offering of 4,000,000 ordinary shares and accompanying warrants at a price of $0.65 per share, aiming to raise approximately $2.6 million for commercial efforts and working capital [1][3]. Group 1: Offering Details - The public offering includes 4,000,000 ordinary shares and warrants to purchase an additional 4,000,000 shares at the same price of $0.65 [1]. - The ordinary warrants will be exercisable immediately and will expire five years from the issuance date [1]. - The expected gross proceeds from the offering are approximately $2.6 million before deducting fees and expenses [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for continuing commercial efforts, working capital, and general corporate purposes [3]. Group 3: Regulatory Information - The offering is being conducted under a registration statement on Form S-1, which was declared effective by the SEC on June 25, 2025 [4]. - A preliminary prospectus has been filed with the SEC and is available on their website [4]. Group 4: Company Overview - Lifeward Ltd. specializes in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities [6]. - The company’s product portfolio includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System [6]. - Founded in 2001, Lifeward operates in the United States, Israel, and Germany [6].

Core Viewpoint - The recent ruling by an Administrative Law Judge establishes that the ReWalk Exoskeleton is a "reasonable and necessary" medical device for enabling paralyzed individuals to walk, paving the way for Medicare coverage and potentially broader commercial insurance access [1][2]. Group 1: Legal and Regulatory Developments - The ALJ ruling supports an appeal by a Medicare beneficiary for coverage of the ReWalk Exoskeleton, affirming its medical necessity for individuals with spinal cord injuries [1]. - This ruling builds on a prior decision by the Centers for Medicare & Medicaid Services (CMS) in April 2024, which finalized a reimbursement pathway for personal exoskeletons [2]. Group 2: Company Innovations and Products - The ReWalk Exoskeleton is noted as the only personal exoskeleton that allows paralyzed individuals to navigate stairs and curbs, in addition to walking in everyday environments [2]. - The latest model, ReWalk 7, received FDA clearance in March 2025 and is now commercially available in the United States [2]. Group 3: Company Mission and Vision - Lifeward aims to transform the lives of individuals with physical limitations through innovative medical technology, focusing on expanding data and programs for the paralyzed community [2][3]. - The company is committed to delivering groundbreaking solutions that empower individuals to regain mobility and improve their quality of life [3].

Lifeward (LFWD) Conference Summary Company Overview - **Company**: Lifeward Limited - **Industry**: Medical Devices, specifically focused on rehabilitation technologies such as exoskeletons and functional electrical stimulation devices Key Points and Arguments Future Growth and Positioning - Lifeward has developed leading innovative technologies aimed at fundamentally changing lives, with a focus on commercialization [4][6] - The company has achieved significant milestones, including Medicare coverage for personal exoskeletons, which positions them for future growth [9][31] Product Portfolio - Lifeward's product lineup includes: - **ReWalk**: A personal exoskeleton for restoring functional walking [12][43] - **AlterG**: An antigravity system for rehabilitation [35][38] - **MyoCycle FES**: A functional electrical stimulation bike for therapy [40][41] - **ReStore Exosuit**: A soft exoskeleton primarily for stroke patients [43][44] Market Access and Reimbursement - The company has made strides in reimbursement coverage, with significant contracts established in the U.S. and Germany [29][31] - Lifeward is focusing on expanding into the commercial market and enhancing relationships with workers' compensation [30][32] Market Size and Potential - The total addressable market for ReWalk in the U.S. is approximately 15,000 eligible candidates, with an additional 2,000 in Germany, indicating a substantial growth opportunity [34] - The company is targeting a broader market with its various products, aiming for profitability through market penetration [34][71] Financial Performance and Path to Profitability - Lifeward expects to achieve revenue between $28 million to $30 million for the current year, with a goal of reaching breakeven at $40 million to $45 million in revenue by 2026 [47][71] - The company has improved gross margins through efficient operations and product mix [48][65] Product Development and Innovation - Lifeward has launched new versions of its products, enhancing user experience with features like smoother movement and better control [18][19][21] - Continuous feedback from users has driven product improvements, emphasizing the importance of user experience in rehabilitation technologies [27][28] Industry Dynamics - The medical device industry is fragmented, presenting opportunities for future consolidation as Lifeward continues to grow and integrate its product lines [46][47] - The company is strategically positioned to leverage its clinic presence to drive referrals and enhance product adoption [67][68] Additional Important Information - Lifeward's products are manufactured in various locations, with ReWalk produced in Israel and other products made in the U.S. [72] - The company has navigated tariff concerns effectively, with protocols in place to mitigate potential impacts [72] This summary encapsulates the key insights from the Lifeward conference, highlighting the company's strategic direction, product offerings, market potential, and financial outlook.